Objective: Current data on primary aldosteronism (PA) from Asian populations are scarce. This cohort study clarifies the attributes of patients with PA in a typical Chinese population.
Design: An observational cohort study.
Methods: The records of patients referred to the Hypertension Clinic from a multi-centre registration in Taiwan from January 1995 to December 2007 were reviewed. All patients with PA were classified into two subtypes: aldosterone-producing adenomas (APA) and idiopathic hyperaldosteronism (IHA); their characteristics were compared.
Results: Our cohort consisted of 346 patients with PA, 255 with APA and 91 with IHA. The initial hypokalaemia (59% in APA vs. 27.5% in IHA, p < 0.0001) and transtubular potassium gradient (TTKG) (6.30 ± 2.41 in APA vs. 4.91 ± 2.03 in IHA, p = 0.01) were higher in the APA group. Baseline plasma aldosterone concentration (PAC) was also significantly different between the two subgroups (49.96 ± 38.15 ng/dl in APA vs. 34.24 ± 21.47 in IHA, p < 0.0001).
Conclusions: In typical Chinese PA patients, the APA subgroup had a higher proportion of hypokalaemia with elevated TTKG and higher PAC as compared with the IHA subgroup. This largest Asian database also demonstrated major differences between the Caucasian and Chinese populations including female predilection, frequent hypokalaemia, and common paralytic myopathy.
Mulatero P., Stowasser M., Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab2004; 89: 1045-1050.
2.
Douma S., Petidis K., Doumas M., et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet2008; 371: 1921-1926.
3.
Rossi GP, Bernini G., Caliumi C., et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol2006; 48: 2293-2300.
4.
Milliez P., Girerd X., Plouin PF, Blacher J., Safar ME and Mourad JJEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol2005; 45: 1243-1248.
5.
Conn JWPresidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med1955 ; 45: 3-17.
6.
Loh KC, Koay ES, Khaw MC, Emmanuel SC and Young WF Jr.Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore . J Clin Endocrinol Metab2000; 85: 2854-2859.
7.
Omura M., Sasano H., Saito J., Yamaguchi K., Kakuta Y. and Nishikawa T.Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism . Hypertens Res2006; 29: 883-889.
8.
Ma JT, Wang C., Lam KS, et al. Fifty cases of primary hyperaldosteronism in Hong Kong Chinese with a high frequency of periodic paralysis. Evaluation of techniques for tumour localisation. Q J Med1986; 61: 1021-1037.
9.
Huang YY, Hsu BR and Tsai JSParalytic myopathy - a leading clinical presentation for primary aldosteronism in Taiwan. J Clin Endocrinol Metab1996; 81: 4038-4041.
Wu VC, Chang HW, Liu KL, et al. Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests. Am J Hypertens2009; 22: 821-827.
12.
Wu VC, Chueh SC, Chang HW, et al. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis2009; 54: 665-673.
13.
Charlson ME , Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM and Hollenberg JPThe Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol2008; 61: 1234-1240.
14.
Chobanian AV , Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA2003; 289: 2560-2572.
Martin JF, Higashiama E., Garcia E., Luizon MR and Cipullo JPHypertensive crisis profile. Prevalence and clinical presentation. Arq Bras Cardiol2004; 83: 131-6; 25-30.
17.
Yen RF, Wu VC, Liu KL, et al. 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results . J Nucl Med2009; 50: 1631-1637.
18.
Levey AS, Bosch JP, Lewis JB, Greene T., Rogers N. and Roth D.A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group . Ann Intern Med1999; 130: 461-470.
19.
Levey AS, Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med2003; 139: 137-147.
20.
West ML, Marsden PA, Richardson RM, Zettle RM and Halperin MLNew clinical approach to evaluate disorders of potassium excretion. Miner Electrolyte Metab1986; 12: 234-238.
21.
Chang HW, Chu TS, Huang HY, et al. Down-regulation of D2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab2007; 92: 1863-1870.
22.
Liao CH, Chueh SC, Lai MK, Hsiao PJ and Chen J.Laparoscopic adrenalectomy for potentially malignant adrenal tumors greater than 5 centimeters. J Clin Endocrinol Metab2006; 91: 3080-3083.
23.
Aiba M., Suzuki H., Kageyama K., et al. Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa. Am J Pathol1981; 103: 404-410.
24.
Omura M., Sasano H., Fujiwara T., Yamaguchi K. and Nishikawa T.Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling . Metab Clin Exp2002; 51: 350-355.
25.
Novitsky YW , Kercher KW, Rosen MJ, Cobb WS, Jyothinagaram S. and Heniford BTClinical outcomes of laparoscopic adrenalectomy for lateralizing nodular hyperplasia. Surgery2005; 138: 1009-1016; discussion 16-17.
26.
Rossi GP, Belfiore A., Bernini G., et al. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension2007; 50: 424-431.
27.
Schwartz GL and Turner STScreening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem2005; 51: 386-394.
28.
Jonsson JR, Klemm SA, Tunny TJ, Stowasser M. and Gordon RDA new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun1995; 207: 565-571.
29.
Su FH, Cheng SH, Li CY, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine2007; 25: 8085-8090.
30.
Walz MK, Gwosdz R., Levin SL, et al. Retroperitoneoscopic adrenalectomy in Conn’s syndrome caused by adrenal adenomas or nodular hyperplasia. World J Surg2008; 32: 847-853.
31.
Hiramatsu K. , Yamada T., Yukimura Y., et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients . Arch Intern Med1981; 141: 1589-1593.
32.
Sartori M., Calo LA, Mascagna V., et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens2006; 19: 373-9; discussion 80.
33.
Mosso L., Carvajal C., Gonzalez A., et al. Primary aldosteronism and hypertensive disease. Hypertension2003; 42: 161-165.
34.
Sechi LA, Novello M., Lapenna R., et al. Long-term renal outcomes in patients with primary aldosteronism . JAMA2006; 295: 2638-2645.
35.
Fardella CE , Mosso L., Gomez-Sanchez C., et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab2000; 85: 1863-1867.
36.
Blumenfeld JD, Sealey JE, Schlussel Y., et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med1994; 121: 877-885.
37.
Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet2008; 371: 2173-2182.
38.
Ribstein J., Du Cailar G., Fesler P. and Mimran A.Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol2005; 16: 1320-1325.
39.
Reincke M., Rump LC, Quinkler M., et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab2009; 94: 869-875.
40.
Letavernier E. , Peyrard S., Amar L., Zinzindohoue F., Fiquet B. and Plouin PFBlood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma . J Hypertens2008; 26: 1816-1823.
41.
Pizzolo F., Trabetti E., Guarini P., et al. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting. J Hum Hypertens2005; 19: 325-327.
42.
Funder JW, Carey RM, Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab2008; 93: 3266-3281.
43.
Young WF Jr.Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology2003 ; 144: 2208-2213.
44.
Willenberg HS, Kolentini C., Quinkler M., et al. The serum sodium to urinary sodium to (serum potassium)2 to urinary potassium (SUSPPUP) ratio in patients with primary aldosteronism. Eur J Clin Invest2009 ; 39: 43-50.
45.
Armanini D. and Fiore C.Some considerations about evolution of idiopathic primary aldosteronism. J Endocrinol Invest2009; 32: 623-625.
